Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Editas Medicine (EDIT) EBIT Margin (2016 - 2025)

Historic EBIT Margin for Editas Medicine (EDIT) over the last 11 years, with Q3 2025 value amounting to 325.44%.

  • Editas Medicine's EBIT Margin rose 1073237400.0% to 325.44% in Q3 2025 from the same period last year, while for Sep 2025 it was 428.71%, marking a year-over-year decrease of 586800.0%. This contributed to the annual value of 777.22% for FY2024, which is 5606700.0% down from last year.
  • According to the latest figures from Q3 2025, Editas Medicine's EBIT Margin is 325.44%, which was up 1073237400.0% from 1440.58% recorded in Q2 2025.
  • Editas Medicine's EBIT Margin's 5-year high stood at 39.9% during Q4 2023, with a 5-year trough of 136952.38% in Q3 2022.
  • Over the past 5 years, Editas Medicine's median EBIT Margin value was 940.09% (recorded in 2023), while the average stood at 15270.04%.
  • In the last 5 years, Editas Medicine's EBIT Margin plummeted by -1363189600bps in 2022 and then skyrocketed by 1360122900bps in 2023.
  • Quarter analysis of 5 years shows Editas Medicine's EBIT Margin stood at 333.71% in 2021, then tumbled by -191bps to 970.72% in 2022, then soared by 96bps to 39.9% in 2023, then tumbled by -282bps to 152.24% in 2024, then plummeted by -114bps to 325.44% in 2025.
  • Its EBIT Margin stands at 325.44% for Q3 2025, versus 1440.58% for Q2 2025 and 1635.1% for Q1 2025.